VRT Research Update — September 19, 2026 (Updated)
Updated Thesis
Vertiv Holdings Co is a global provider of critical digital infrastructure for data centers, communication networks, and industrial applications, spanning AC and DC power management, thermal cooling, integrated rack systems, and lifecycle services under brands including Liebert, NetSure, Geist, and Avocent, with roughly 34,000 employees and a global footprint across the Americas, Asia Pacific, and EMEA. The business quality is high: return on equity is 42.1%, TTM operating margin is 19.1%, TTM net margin is 15.1%, and revenue grew 24.1% year over year in the most recent quarter while earnings grew 53.5% in the same period, reflecting genuine operating leverage and exposure to secular AI and hyperscale data-center buildouts. The stock is not cheap, however: at $253.28 it trades at 8.49x sales, 56.24x trailing earnings, 33.31x free cash flow, and 38.81x EV/EBITDA, and the valuation regime is very expensive versus its own five-year history.
The investment grade as of this refresh is C — average business quality. A-tier business, C-tier valuation with only 8.2% upside to $274.15 fair value.
Grade Change
In this research cycle, the investment grade for Vertiv Holdings Co moved from B to C. A-tier business, C-tier valuation with only 8.2% upside to $274.15 fair value.
Key Metrics at a Glance
- Revenue growth: +24.1% year over year
- Net margin: 15.1%
- Fair value upside: +8.2% to our estimate of $274
Current price: $253.28
These figures reflect our most recent data pull and are one input into a multi-factor valuation framework.
Our 12–18 Month Outlook
Quality companies held over a multi-year horizon benefit from compounding fundamentals and the patience to ride through short-term volatility. Vertiv Holdings Co remains in our covered universe with a average-quality assessment. We update research when material data changes — earnings revisions, management shifts, or regime changes in valuation — not on every price fluctuation.
Long-term accumulation of quality businesses at fair or better prices is the core of the Patient Accumulator approach. Research updates like this one inform whether to add, hold, or wait for a better zone — not whether to react to short-term price moves.
[View full VRT research →](/stocks/VRT)